Is Hims & Hers the next big player in telehealth? Our experts break down its business model, growth potential, and the risks ...

Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

Technological innovation and personalized care are transforming Hims & Hers into a proactive health platform. Read why I ...

The Microdose GLP-1Rx Program will offer low-dose GLP-1 prescriptions combined with behavioral coaching, clinical monitoring and medication management.

In its updated report, Hims & Hers Health, Inc. (NYSE:HIMS) said revenues increased by 73 percent to $544.8 million from $315 ...

With 14 new lawsuits filed and 132 total complaints across 40 states, Novo Nordisk is intensifying efforts to protect ...

US stocks end lower after data show higher prices and lower employment. Investors also weigh earnings and Trump tariff threats.

Ten stocks mirrored a lackluster performance in the broader market on Tuesday, posting hefty double-digit losses primarily due to disappointing earnings performance and a lower growth outlook for the ...

Gibbs Mura encourages investors to contact us about their legal rights and options in the Hims & Hers Health, Inc. (NYSE: HIMS) Securities Class Action Lawsuit . What Should Hims & Hers Investors Do?

Hims & Hers Health posted an increase in profit and revenue for the second quarter on growth in subscribers using personalized treatment plans. The telehealth-consultation platform on Monday posted a ...

Live Updates Live Coverage Has Ended Tuesday Wrap-up 4:27 pm The Vanguard S&P 500 ETF closed at 577.35 Tuesday, down 0.5%.